Researchers at the University of Pittsburgh have developed a novel drug delivery system using boryl ethers that release therapeutic agents in response to oxidative stress. This innovative approach targets disease states characterized by oxidative stress, such as cancer, diabetes, and neurodegenerative conditions. The pro-drugs can be engineered to include cell-targeting functional groups, and the by-products of the drug release are non-toxic, making this a promising strategy for targeted therapy.
Description
The technology involves the use of alpha-boryl ethers that release drugs upon exposure to hydrogen peroxide, a marker of oxidative stress. This mechanism avoids the release of toxic quinone methides, which are generated by other peroxide-sensitive prodrugs. The system uniquely releases ketones and aldehydes under oxidative conditions, and the release rates can be adjusted through rational structural modifications. This design ensures that the drugs are released specifically in oxidatively stressed environments, enhancing the efficacy and safety of the treatment.
Applications
• Targeted drug delivery for cancer therapy
• Treatment of diabetes and related complications
• Therapeutic interventions for neurodegenerative diseases
• Enhanced drug delivery in radiation therapy
Advantages
This technology provides a targeted drug delivery system that responds to oxidative stress, avoids the release of toxic by-products, and allows for adjustable release rates. The ability to incorporate cell-targeting functional groups further enhances the specificity and effectiveness of the treatment. This approach has the potential to improve therapeutic outcomes and reduce side effects in patients with diseases characterized by oxidative stress.
Invention Readiness
The technology is currently at the prototype stage, with initial demonstrations showing successful release of fluorophores in cells upon stimulation with hydrogen peroxide. Further development and testing are ongoing to optimize the drug delivery system and validate its efficacy in preclinical models.
IP Status
https://patents.google.com/patent/US11738088B2
